Investor Presentaiton

BIOND BIOLOGICS BND-22 Target Product Profile Product Description E Scientific Rationale MOA/Clinical Pharmacology • • Ig-Like Transcript 2 (ILT2) blocking antibody Strategic Context / Differentiation Novel multi-cell checkpoint inhibitor enhancing the anti-tumor activity of both the innate and adaptive immune systems with the potential to overcome PD-1 resistance Preclinical data support combination with cetuximab, and PD-1 blockers • Binding of MHC-I molecules to the ILT2 receptor expressed by macrophages, T-cells and NK cells inhibits anti-tumor effector functions of these cells Upregulation of ILT2 ligands, (E.g., HLA-G) occurs in multiple tumor types and is associated with poor prognosis Indication(s) and patient 3 population HLA-G-expressing solid tumors Patients with unrespectable or metastatic disease, with disease progression following prior systemic therapies BND-22 is an antibody that binds to the ILT2 receptor and blocks its interaction with MHC-I molecules Releases ILT2 pathway-mediated inhibition of the innate and adaptive anti-tumor immune response Blocking ILT2 activity enhanced macrophage phagocytosis and NK and T cells cytotoxicity activity against cancer cells Extensive biomarker/ PD marker strategy in place # Stage Biond Biologics and Sanofi enter into global licensing agreement Q3 2020 Phase I initiated Q1 2021 Biond Biologics Corporate Presentation | May 2021 | Non-confidential 13

View entire presentation